EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Expanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis

Nicolas Goossens iD, Osvaldo Ulises Garay iD, Cyrill Wolf, Louisa Elena Ambüehl, Vanessa Kugler, François R Girardin iD

Swiss Medical Weekly · 2026-05-28 · 156 (5) · 4469

DOI: 10.57187/4469 ↗

At a glance

Journal article in Swiss Medical Weekly, published online on 2026-05-28. Written by Nicolas Goossens and 5 co-authors. Institution: Division of Gastroenterology and Hepatology and Division of Transplantation, Geneva University Hospitals, Geneva, Switzerland. Major MEDLINE topics: Carcinoma, Hepatocellular, Cost-Benefit Analysis, Liver Neoplasms, Early Detection of Cancer. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

BACKGROUND: European and Swiss guidelines recommend hepatocellular carcinoma surveillance of high-risk patients every 6 months using ultrasound (US), with/without α-fetoprotein (AFP). Other surveillance strategies are available, but evidence of their comparative cost-effectiveness is lacking. This study evaluated the cost-effectiveness of current hepatocellular carcinoma surveillance strategies in Switzerland, including the novel GAAD (gender [biological sex], age, α-fetoprotein, protein induced by vitamin K absence or antagonist-II [PIVKA-II]) serum-based algorithm in high-risk patients. METHODS: A micro-simulated Markov model estimated the cost-effectiveness of hepatocellular carcinoma surveillance strategies (no surveillance, US, US+AFP, GAAD) performed at 6-monthly intervals in a simulated cohort of 100,000 patients with compensated liver cirrhosis over a lifetime horizon. Performance parameters were sourced from published meta-analyses and multicentre study data. Epidemiological parameters were estimated based on literature identified during a previous systematic literature review. Similarly, utility parameters were sourced from published literature. Costs were sourced from TARMED, the Analysis List, the Swiss Federal Statistical Office, publicly available data and published literature. Primary outcomes were life years lived, quality-adjusted life years, and costs per patient and per cohort. The cost-effectiveness of each strategy was analysed through incremental cost-effectiveness ratios at a cost-effectiveness threshold of Swiss Franc (CHF) 100,000/quality-adjusted life year. RESULTS: Overall, the total costs and quality-adjusted life years per patient, respectively, were CHF 43,493.61 and 5.893 for no surveillance; CHF 48,702.79 and 6.018 for US; CHF 49,980.60 and 6.042 for US+AFP; and CHF 49,983.10 and 6.048 for GAAD. Compared with US+AFP and US alone, GAAD was cost-effective, with higher quality-adjusted life years and the highest rate of early-stage hepatocellular carcinoma detection (56%). Compared with no surveillance, incremental cost-effectiveness ratios for US, US+AFP and GAAD were considered to be cost-effective, ranging from CHF 41,509.01 to CHF 43,321.81. CONCLUSIONS: The current model indicates that hepatocellular carcinoma surveillance with any of these strategies was cost-effective in Switzerland. GAAD was nearly cost-neutral versus US+AFP, although these findings were dependent on the performance of GAAD and operator-dependent US combined with AFP. Compared with US alone, GAAD was the most cost-effective strategy. Further investigations are required to confirm these findings and to optimise hepatocellular carcinoma surveillance.

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularCost-Benefit AnalysisLiver NeoplasmsEarly Detection of CancerHumansCost-Effectiveness AnalysisSwitzerlandFemaleMalealpha-FetoproteinsMarkov ChainsQuality-Adjusted Life YearsMiddle AgedUltrasonographyBiomarkersAgedProthrombinAlgorithmsProtein Precursors

Substances

alpha-FetoproteinsBiomarkersProthrombinacarboxyprothrombinProtein Precursors

Authors and institutions

  • Division of Gastroenterology and Hepatology and Division of Transplantation, Geneva University Hospitals, Geneva, Switzerland.
  • Global Access & Policy, Roche Diagnostics International, Rotkreuz, Switzerland.
  • Roche Diagnostics (Schweiz) AG, Switzerland.
  • Department of Chemistry, University of Zurich, Zurich, Switzerland.
  • Roche Pharma (Schweiz) AG, Basel, Switzerland.
  • Head of Division of Clinical Pharmacology, Department of Internal Medicine & Department of Laboratory Medicine and Pathology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.

ORCID profiles: Nicolas Goossens, Osvaldo Ulises Garay, François R Girardin

Cite

APA

Goossens, N., Garay, O. U., Wolf, C., Ambüehl, L. E., Kugler, V., & Girardin, F. R. (2026). Expanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis. Swiss Medical Weekly, 156(5), 4469. https://doi.org/10.57187/4469

Vancouver

Goossens N, Garay OU, Wolf C, Ambüehl LE, Kugler V, Girardin FR. Expanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis. Swiss Medical Weekly. 2026;156(5):4469. doi:10.57187/4469

BibTeX
@article{Goossens2026,
  author = {Goossens, Nicolas and Garay, Osvaldo Ulises and Wolf, Cyrill and Ambüehl, Louisa Elena and Kugler, Vanessa and Girardin, François R},
  title = {Expanding hepatocellular carcinoma surveillance strategies in high-risk patients in Switzerland: a cost-effectiveness analysis},
  journal = {Swiss Medical Weekly},
  year = {2026},
  volume = {156},
  number = {5},
  pages = {4469},
  doi = {10.57187/4469}
}
Start for free →